placeholder to show this banner

ashbanner

Arcellx’s anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T to be investigated in multiple myeloma that utilizes our novel and compact D-Domain binder.

Arcellx is pleased to present new positive data for is iMMagine-1 study in patients with relapsed and/or refractory multiple myeloma at the EHA2025 Congress in Milan on June 14, 2025.

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial

Publication #S201
EHA 2025 Resources

Arcellx Announces New Positive Data for the iMMagine-1 Study in Patients with RRMM
Announced
5/14/25

Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results
Posted
6/13/25

iMMagine-1 Oral Presentation
Published
6/14/25

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial

EHA2025 Presentation Details
Speaker:
Gurbakhash Kaur, M.D., Assistant Professor of Internal Medicine, Mount Sinai Health System
Session Title:
s431 Treatment of relapsed and/or refractory multiple myeloma (RRMM)
Session Date:
June 14, 2025
Session Time:
17:00-18:15 CEST
Publication Number:
S201
Presentation Title:
S201 Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1

Press Releases
Presentations